PROGRAM - IASLC · 2020. 8. 23. · Tejas Patil P05 Real World Data on Safety and Efficacy of 160 mg Daily Dose of Osimertinib in Patients with Sensitizing EGFR Mutant NSCLC with

1

#TTLC20FEBRUARY 19-22, 2020 | SANTA MONICA, CALIFORNIA

PROGRAMFEBRUARY 19-22, 2020 | SANTA MONICA, CALIFORNIA

2020 Targeted Therapiesof Lung Cancer Meeting

FEBRUARY 19-22, 2020 | SANTA MONICA, CALIFORNIA


THANK YOU TO OUR TOP SPONSORS!

D I A M O N D

P L A T I N U M

TABLE OF CONTENTSWELCOME 4

Letter from the President & CEO 4 Letter from Conference Chairs 5

GENERAL CONFERENCE 6INFORMATION

Invited Speakers, Abstract and Poster Presenter Information 8 Venue Floor Plans 10

POSTERS 11

EDUCATIONAL AWARDS 13

SPONSORS & EXHIBITORS 13Exhibitors & Floor Plan 14 Exhibitor Descriptions 16

18SCIENTIFIC PROGRAM

4

WELCOME Dear Colleagues

and Friends,Given the rapid pace of change in the lung cancer field, investigators and clinicians face continual pressure to remain abreast of the latest advances in treatment and therapy. The IASLC Targeted Therapies of Lung Cancer Meeting (TTLC) has long sought to assist with that ongoing challenge, providing a forum for the lung cancer community to learn about the newest treatments and how they can be most effectively incorporated into clinical practice.

This year, TTLC is proud to celebrate its 20th anniversary, and on behalf of the IASLC leadership, Board of Directors and conference organizers, we want to thank you for joining us in Santa Monica for this unique event. Over the next three days, you will get an exclusive look at relevant targets for new therapies; data on pre-clinical and early clinical statistics for each of the drugs directed against these targets; presentations on early predictive biomarkers; debates on controversial topics and much more.

It is our wish that you will leave this meeting inspired and hopeful about the latest advances occurring in the lung cancer field. We hope that you will also feel more confident in your grasp of this complex and ever-evolving treatment landscape, not to mention more capable in your ability to affect real and positive change in the lives of your patients.

While you’re here, we encourage you to take the time to engage with your friends and peers, as well as to forge new relationships and collaborations. And if you are active on social media, please share what you are learning with the conference’s hashtag: #TTLC20. It is only by coming together as a community that we will be able to continue making substantive progress against this disease that affects so many around the world.

Once again, we’re so pleased that you have decided to join us for this important event. Welcome to Santa Monica and welcome to the IASLC 2020 Targeted Therapies of Lung Cancer Meeting.

Tetsuya Mitsudomi, MD Dave Mesko, MBA President, IASLC Chief Executive Officer

5

Dear Colleagues and Friends, On behalf of the International Association for the Study of Lung Cancer (IASLC) we are pleased to welcome you to the IASLC 2020 Targeted Therapies of Lung Cancer Meeting (TTLC 2020) at the Fairmont Miramar Hotel & Bungalows. The IASLC Targeted Therapies of Lung Cancer meeting is a dynamic meeting with a long tradition, and over 600 participants will join us this year to share information about ongoing clinical trials of the newest therapies for lung cancer. The meeting presenters summarize the data on relevant targets for new therapies and share data on preclinical and early clinical data for each of the drugs directed against these targets.

We also would like to extend our gratitude and thanks to all sponsors and exhibitors for their continued support to the Targeted Therapies of Lung Cancer Meeting and the IASLC. Without them this conference would not be possible.

Thank you for joining us in Santa Monica.

We look forward to hosting all of you over the next couple of days.

Best Regards,

TTLC 2020 Conference Chairs

Paul A. Bunn, Jr., MD

Roy S. Herbst, MD, PhD

Suresh S. Ramalingam, MD

Leora Horn, MD

Suresh Ramalingam, MDLeora Horn, MDRoy Herbst, MD, PhDPaul A Bunn Jr., MD

62020 TARGETED THERAPIES OF LUNG CANCER MEETING

GENERAL CONFERENCE INFORMATIONCONFERENCE VENUE Fairmont Miramar Hotel & Bungalows, 101 Wilshire Blvd, Santa Monica, CA 90401, United States

REGISTRATION AND IASLC INFORMATION DESK, HOTEL LEVEL

Wednesday, February 19 (Hotel Lobby) 14:00 – 19:00

Thursday, February 20 (Wedgewood Foyer) 06:30 – 19:00

Friday, February 21 (Wedgewood Foyer) 06:30 – 18:40

Saturday, February 22 (Wedgewood Foyer) 06:00 – 12:15

7

EXHIBITION Exhibition Hall, Hotel Level, Starlight Foyer

February 19 17:00 – 18:00, Welcome Reception

February 20 09:30 – 19:00

February 21 09:30 – 17:00

February 22 08:30 – 12:15

IASLC VIRTUAL LIBRARY All approved presentation slides and abstracts will be made available as a Virtual Meeting in the IASLC Virtual Library. The TTLC 2020 Virtual Meeting is included in your registration and can be accessed through library.IASLC.org.

Your personal Virtual Meeting Access Code is the same as your Delegate ID Number and can be found on your badge or through your TTLC 2020 registration confirmation email. After you enter your Access Code and confirm your account details, you’ll be able to view the presentations that have been marked approved for viewing and marked as “Now Available.” To access the Virtual Library, please visit library.IASLC.org.

Given the sensitive nature of some of the presentations at this meeting, certain presentations/slides may have confidentiality restrictions and will not be shared in the Virtual Library

ABSTRACTS Accepted abstracts will be presented in oral sessions, the poster reception and during networking breaks.

ACCREDITATIONThe IASLC TTLC 2020 Meeting is not accredited and does not provide CME credits or certifications for attending sessions.

ATTIRE Business casual is appropriate for all sessions. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

BADGES AND ACCESS CONTROL Attendees are requested to wear their name badges at all times in order to participate in the Scientific Sessions and Exhibition. A $50 USD fee applies for any name badge reprints due to lost name badges.

BREAKFAST A light breakfast will be provided in the Wedgewood Ballroom from 06:30 – 07:30 on Thursday and Friday, and 06:00 – 07:00 on Saturday.

CELL PHONES As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.


IASLC SOCIAL MEDIA ACCOUNTS TO FOLLOWTwitter: @IASLC

Facebook: FACEBOOK.COM/IASLC

Youtube: IASLC

Conference Hashtag: #TTLC20

SOCIAL MEDIA POLICYGiven the sensitive nature of some of the presentations at this meeting, we would like to remind attendees that specific presentations may not be shared on any media. Presentations and/or slides that may NOT be shared will be noted at the beginning of each presentation and/or on each slide stating that the material may not be shared. Attendees will be reminded of this policy at the beginning of each session.

VIDEO INTERVIEWSVideo interviews will be conducted in the Wilshire III Ballroom on the lower level.

WIRELESS INTERNET Wireless internet will be provided in the meeting and exhibit space.

Network: Fairmont

Password: TTLC20

Disclaimer: The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.

INFORMATION FOR INVITED SPEAKERS, ABSTRACT AND POSTER PRESENTERS

Disclosure Information All speakers must include a slide with their financial disclosure information. Without a disclosure slide you will not be allowed to present.

Presentation Slide Template All speakers are encouraged to use the IASLC/TTLC presentation slide template for their presentation.

Slide SubmissionThe IASLC requested that you submit your PowerPoint slides prior to the meeting. If you did not submit your PowerPoint slides prior to or have revised slides, please provide your presentation slides to the technicians in the Starlight Ballroom at least 2 hours prior to your presentation. The use of personal laptops for presentations is not allowed as it can cause technical delays and cut into a presenter’s time.

At the time of submission, you will be asked to provide permission to the IASLC to a royalty-free, worldwide, perpetual, irrevocable, nonexclusive and sublicensable license to use, reproduce, publish, translate, distribute, sell and display the presentation. The IASLC realizes that certain slides might include confidential data and will allow those slides to be removed from any broadcast or distribution of the presentation slides. However, you must indicate at the time of submission whether any individual slide contains such confidential information.

9

Poster PresentationsAll Poster Presentation boards are located in the Wedgewood Ballroom, Hotel Level.

Each poster is identified with a poster number that corresponds with the pre-assigned poster number published in this program book. Please visit the IASLC Information & Poster Desk to confirm poster numbers or ask any questions.

POSTER SETUP TIME Thursday, February 20, 06:00 – 07:45

POSTER TAKE DOWN TIME Saturday, February 22, 2020, after 09:30

AUTHOR STANDBY TIME

Thursday, February 20

10:00 – 10:20 (Coffee Break)

15:00 - 15:20 (Coffee Break)

17:55 – 18:55 (Poster Viewing Reception)

Friday, February 21

09:55 – 10:15 (Coffee Break)

16:05 – 16:25 (Coffee Break)

Saturday, February 22 09:15 - 09:30 (Coffee Break)


Ocean I

Wilshire I

Ocean II

Wilshire IIWilshire IIIWilshire IV

Starlight Ballroom

Lower Level Meeting SpaceWilshire & Ocean Rooms

Wedgewood Ballroom

Lobby Lounge

FIG Restaurant

Jones Library

Starlight Foyer

VENUE FLOOR PLANS

Hotel Level

Lower Level

11

P01Atypical EGFR Mutations and Co-mutations in Non-Small Cell Lung Cancer Patients Treated with OsimertinibJacqueline Aredo

P02Resistance to EGFR TKI Therapy via Newly Acquired Oncogenic Drivers: Case Series and Review of the Literature of Treatment OutcomesNicholas Giustini

P03Network-based Transcriptome Analysis to Predict Primary Tyrosine Kinase Inhibitor (TKI) Resistance in EGFR-Mutant Lung Adenocarcinomas (LUAD)Brian Henick

P04The Role of Continuing Osimertinib with Platinum Doublet Chemotherapy in Patients with Epidermal Growth Factor Receptor (EGFR) Positive Non-Small Cell Lung Cancer Who Have Progressed on OsimertinibTejas Patil

P05Real World Data on Safety and Efficacy of 160 mg Daily Dose of Osimertinib in Patients with Sensitizing EGFR Mutant NSCLC with Brain or Leptomeningeal MetastasisDipesh Uprety

P06Genomic Correlates of Differential Response to EGFR-Directed Tyrosine Kinase InhibitorsNatalie Vokes

P07Clinical Outcomes and Co-Occurring Genetic Alterations in Patients with EGFR Exon 20 Insertion MutationsGabriela Bravo Montenegro

P08Phase I Study of Combination Immunotherapy with Ipilimumab and Nivolumab in Patients with Recurrent Extensive Stage Small Cell Lung Cancer (SCLC)Matthew Austin

P09Outcomes to First-Line Pembrolizumab in Patients with Non-Small-Cell Lung Cancer and a Poor Performance StatusJoao Victor Alessi

P10Immune Checkpoint Blockade Response in Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor L858R MutationsAmy Cummings

P1 1CDKN2A Loss Predicts Immunotherapy Response in Stage III/IV NSCLCStanley Gutiontov

P12Determination of Biological Responders Among Those With Radiological Stable Disease to Immune Checkpoint InhibitorsJia Luo

P13Consolidation with Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)Shetal Patel

P14Clinical Outcomes of EGFR+ NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI)Andrew Piper-Vallillo

P15 Longitudinal Analysis of PD-L1 and HLA I in Circulating Tumor Cells from Patients with Metastatic Non-Small Cell Lung Cancer Receiving Checkpoint Inhibitor TherapyNan Sethakorn

P16Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with Brain Metastases Treated with Pembrolizumab-Based TherapyLova Sun

P17Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud’s-Like PhenomenonMitchell von Itzstein

P18ctDNA as a Diagnostic and Prognostic Marker in Patients with KRAS Mutant Non-Small Cell Lung Cancer Yonina R. Murciano-Goroff

P19Dynamic Heterogeneity in [18F]-FDG PET Radiomic Features Before and After Neoadjuvant Nivolumab and Association with Major Pathologic Response in Early Stage Non-Small Cell Lung CancerErica C. Nakajima

P20Predictive Value of High-Risk Clinicopathologic Features for Adjuvant Chemotherapy in Early-Stage Lung CancerRanjan Pathak

P21Trial in Progress: Circulating Tumor DNA as a Predictive Biomarker to Individualize Therapy in Patients with Inoperable Stage III Non-Small Cell Lung CancerNikhil Shukla

P22The increasing Role of ALK Positive in improving Outcomes for ALK-Positive PatientsColin Barton

POSTERS


P23Investigating the Role of BCL-2 in ALK-Rearranged Non-Small Cell Lung Cancer Treated with ALK-Directed Targeted TherapyNathaniel Myall

P24JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in primary MET Exon14 Skipping Non-small Cell Lung CancerDan Zhao

P25Phase II Study of Pevonedistat Monotherapy in Previously Treated Patients with Malignant Mesothelioma Harboring Alterations in NF2Michael Offin

P26Role of mTOR Inhibitor Everolimus in the Management of Metastatic Thymic Epithelial Tumors and the Use of a Computational Biological Model to Select Patients for TreatmentJessica Hellyer

P27The Tumor Immune Microenvironment (TIME) in EGFR—driven Lung Adenocarcinoma: Implications for Disease RecurrenceMaya Khalil

P28Functional Profile of Major Tumor Infiltrating Lymphocyte Subsets and PD-L1 Expression in Lung Cancer-Associated Brain MetastasesBenjamin Lu

P29Monocytes and Macrophages Promote Tyrosine Kinase Inhibitor Resistance and Sustained pERK signaling ALK+ Non-Small Cell Lung CancerErin Schenk

P30The Lung Microbiome and Metabolome are Altered in Lung Cancer Patients Frank Weinberg

13

SPONSORS & EXHIBITORS

1. Joao Victor Alessi

2. Jacqueline Aredo

3. Matthew Austin

4. Gabriela Bravo Montenegro

5. Yvonne Chao

6. Amy Cummings

7. Nicholas Giustini

8. Stanley Gutiontov

9. Jessica Hellyer

10. Brian Henick

11. Sushma Jonna

12. Jacob Kaufman

13. Maya Khalil

14. Emily Lebow

15. Benjamin Lu

16. Jia Luo

17. Yonina R Murciano-Goroff

18. Nathaniel Myall

19. Erica Nakajima

20. Michael Offin

21. Shetal Patel

22. Ranjan Pathak

23. Tejas Patil

24. Andrew Piper-Vallillo

25. Biagio Ricciuti

26. Nan Sethakorn

27. Nikhil Shukla

28. Lova Sun

29. Dipesh Uprety

30. Natalie Vokes

31. Mitchell von Itzstein

32. Frank Weinberg

33. Dan Zhao

CONGRATULATIONS to our TTLC 2020

Educational Award Winners: D I A M O N D

P L A T I N U M

G O L D

S I LV E R

B R O N Z E

OPENING RECEPTION

COFFEE BREAKS


O

NCO

LOG

YLEA

RN

ING

NETW

OR

K

7

9

1314

E N T R A N C E

STARLIGHT BALLROOM

SCIENTIFICSESSIONS

AM

GEN

BAYER TAKEDAIASLC BMS ASTRAZENECA

MERCK

GENENTECH

NO

VOCU

REBO

EHRI

NG

ERR

ING

ELH

EIM

PFIZER

10

15

1

2 3 4 5 6

Booth # EXHIBITOR Booth # EXHIBITOR1 Amgen 3 IASLC

5 AstraZeneca 7 Merck

2 Bayer 13 Novocure

4 BMS 10 Oncology Learning Network

14 Boehringer Ingelheim 9 Pfizer

15 Genentech 6 Takeda

STARLIGHT BALLROOMSCIENTIFICSESSIONS

Exhibitors & Floor Plans

Exhibit Hall, Starlight Foyer

15

Exhibitor Descriptions

Booth

#1Amgen Oncology is searching for answers to incredibly complex questions that will advance care and improve lives for cancer patients and their families. Our research drives us to understand the disease in the context of the patient's life – not just their cancer journey – so they can take control of their lives.

For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.

At Amgen, we are driven by our commitment to transform the lives of cancer patients and keep them at the center of everything we do.

Booth

#5AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

Booth

#2Bayer is a global Life Sciences leader in cardiopulmonology, hematology, neurology, oncology and women’s health. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing innovative therapies and delivering first-in-class educational and support programs to meet their needs. For more information, visit www.bayer.us.

Booth

#14At Boehringer Ingelheim we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.

Booth

#4Bristol-Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.


Booth

#15Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

Booth

#3The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.IASLC.org for more information.

Booth

#7For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases.

Today, Merck continues be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

Booth

#13Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

17

Booth

#10Oncology Learning Network® is an online resource for the latest developments in oncology practice, providing a customized experience for readers to stay informed about the topics that matter most to them. Through clinical insights, peer-reviewed journal articles, interactive features, research news updates, accredited continuing education (CE) programs, and professional live meetings and events, Oncology Learning Network serves as a collaborative learning and networking environment for a multidisciplinary community of oncology medical professionals. See what’s on it for you: www.ONCNET.com.

Booth

#9At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma.

Booth

#6The Takeda Oncology mission remains constant—we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Delivering on the unique needs of each person with cancer has been at the core of our oncology business since our inception, and it remains at the very heart of our commitment, research and outreach. The strength and bravery of these individuals inspire and compel us every day.

Alongside our boundary-pushing global R&D unit, Takeda Oncology’s proven commercialization capabilities allow us to quickly respond to the diverse and ever-changing needs of patients, healthcare providers and health systems around the world. We are a force of more than 2,000 dedicated oncology professionals, driven by a patient-focused entrepreneurial spirit and commitment to agility.

We are working every day to achieve our aspiration to cure cancer.


FAIRMONT MIRAMAR HOTEL | SANTA MONICA, CALIFORNIA Co-chairs: Paul A. Bunn, Jr., MD | Roy S. Herbst, MD, PhD | Suresh S. Ramalingam, MD | Leora Horn, MD

SESSIONS: STARLIGHT BALLROOM | MEALS: WEDGEWOOD BALLROOM

WEDNESDAY, FEBRUARY 19, 2020

Start End Event Presenter

14:00 19:00 REGISTRATION

17:00 18:00 WELCOME RECEPTION

18:00 19:00 DINNER

19:00 19:05 CEO Welcome Dave Mesko

19:05 19:10 President's Welcome Tetsuya Mitsudomi

19:10 19:30 Scientific Talk 1: Lung Cancer Mortality Reduction 2020 Report Helmneh Sineshaw

19:30 19:50 Scientific Talk 2: Advances in Thoracic Cancer – Past, Present, and Future: An FDA Perspective Harpreet Singh

19:50 20:05 20 Years of Targeted Therapies: Evolving Targets and Innovative Therapies

Paul A. Bunn Jr., Roy Herbst, Leora Horn, Suresh Ramalingam

THURSDAY, FEBRUARY 20, 2020


06:30 07:30 BREAKFAST

7:30 9:45 Session 1 - EGFR TKIs Chairs: Joan Schiller, Thomas Lynch

7:30 7:40 Science Pasi Janne

7:40 7:45 Zn-e4 Karen Reckamp

7:45 7:50 HS10296 Lyudmila Bazhenova

7:50 7:55 Rezivertinib (BPI-7711) Sai-Hong Ou

7:55 8:00 Lazertinib Keunchil Park

8:00 8:05 Tak788 Howard West

8:05 8:10 Poziotinib Jacqulyne Robichaux



19



8:10 8:15 Osimertinib Lecia Sequist

8:15 8:20 Tarloxitinib Viola Zhu

8:20 8:25 Pyrotinib George Simon

8:25 8:30 CLN-081 (TAS6417) Helena Yu

8:30 8:35 DZD9008 Deborah Doroshow

8:35 8:40 EGFR + MET (Savolitinib, Tepotinib, Capmatanib) Mark Kris

8:40 8:45 JNJ61186372 Rachel Sanborn

8:45 8:50 Olecumab (anti-CD73) Sarah Goldberg

8:50 8:55 Atezo/bev/CT and other 2vs3 or 4 Mark Socinski

8:55 9:00 Afatinib + Necitumumab Sukhmani Padda

9:00 9:05 Dasatinib Hatim Husain

9:05 9:10 Navitoclax Elaine Shum

9:10 9:15 Sepanisertib Penelope Bradbury

9:15 9:20 Alisertib Trever Bivona

9:20 9:25 CB 839 Telaglenastat Greg Otterson

9:25 9:30 Platinum doublet Ronald Natale

9:30 9:35 Temozolomide + TKI for recurrent brain metastases Jose Pacheco

9:35 9:45 DISCUSSION

9:45 10:00 Debate 1 - What Do You Give to Patients With EGFR Mutation in the First Line?”Moderators: Keunchil Park, Jianjun Zhang

9:45 9:50 TKI + VEGF Howard West

9:50 9:55 TKI alone Mark Kris

09:55 10:00 Chemo plus TKI Philip Bonomi

10:00 10:20 COFFEE BREAK, EXHIBITS & POSTERS

10:20 12:30 Session 2 - Small Cell Lung CancerChairs: Wolf Lindwasser, John Minna

10:20 10:30 Science Charles Rudin

10:30 10:35 Nivolumab Combinations Ticiana Leal

10:35 10:40 Durvalumab +/- Chemo Jonathan Goldman




10:40 10:45 Atezolizumab +/- Chemo Stephen Liu

10:45 10:50 Pembrolizumab +/- Chemo Victoria Lai

10:50 10:55 Nivolumab + temozolomide Dwight Owen

10:55 11:00 Dinutuximab Martin Edelman

11:00 11:05 Lurbinectedin William Petty

11:05 11:10 PARP Inhibitors Ben Drapkin

11:10 11:15 Olaparib + temozolomide Anna Farago

11:15 11:20 AMG 757 (DLL3) + AMG 119 (DLL3) (CAR-T) Hossein Borghaei

11:20 11:25 GD-2 CAR Jared Weiss

11:25 11:30 Irinotecan (onidyve) Paul A. Bunn Jr.

11:30 11:35 PAX5 (BSAP) Ravi Salgia

11:35 11:40 INCB05987 +/- IO (next to IO at top) Young Kwang Chae

11:40 11:45 Somatostatin Receptor Jonathan Lehman

11:45 11:50 AZD2811 + other Aurora Kinase Inhibitors Carl Gay

11:50 11:55 RRx-001 Daniel Morgensztern

11:55 12:00 Chemo-RT Roy Decker

12:00 12:05 Chemo + IO + RT Helen Ross

12:05 12:10 Role of PCI in era of chemo IO Kristin Higgins

12:10 12:15 Cell free DNA Wade Iams

12:15 12:20 TAXOL + APG-1252 (Bcl-xL) Gregory Kalemkerian


12:30 13:30 LUNCH

13:30 15:00 Session 3 - Immune Checkpoint InhibitorsChairs: David Stewart, Ralph Zinner

13:30 13:40 Science Roy Herbst

13:40 13:45 Long term follow up single agent Neal Ready

13:45 13:50 Long term follow up chemo-combo David Ettinger

13:50 13:55 Sensitivity and resistance STK11 Ferdinandos Skoulidis

13:55 14:00 Sensitivity and resistance HLA microglobulin Katerina Politi

14:00 14:05 Optimal duration of therapy David Spigel

21



14:05 14:10 Optimal IO endpoints Yu Shyr

14:10 14:15 ATL001 Rosalyn Juergens

14:15 14:20 ADXS 503 Jennifer Carlisle

14:20 14:25 GRN 1201 Jyoti Patel

14:25 14:30 M7824 Leora Horn

14:30 14:35 KN046 (PDL1-CTLA4 bispecific) Vamsidhar Velcheti

14:35 14:40 PBF 1129 Dwight Owen

14:40 14:45 CXCL21 Dendritic Vaccine Aaron Lisberg

14:45 14:50 Neo-PV-01 Kathryn Arbour



15:20 15:45 Debate 2 - Optimal therapy for stage 4 NSCLC patient with low PD-L1 expression (1-49%)Moderators: Raymond Osarogiagbon, Chandra Belani

15:20 15:25 Chemo + PD-1 inhibition Karen Reckamp

15:25 15:30 Ipi plus Nivo Matthew Hellman

15:30 15:35 PD-1 Inhibition Lawrence Einhorn

15:35 16:30 Session 4 - Biomarker PanelChairs: Dara Aisner, Eva Szabo

15:35 15:40 IHC/Neoadjuvant Ignacio Wistuba

15:40 15:45 Multiplex Kurt Schalper

15:45 15:50 Next Generation Diagnostics for Lung Cancer; Beyond IHC and NGS David Rimm

15:50 15:55 Tissue and the Issue (blueprint) Fred Hirsch

15:55 16:00 ctDNA Max Diehn

16:00 16:05 TMB Tissue Hossein Borghaei

16:05 16:10 TMB Blood David R. Gandara

16:10 16:15 RT + IO Andrea Bezjak

16:15 16:20 WIN Consortium Amir Onn





16:20 17:55 Session 5 - KRAS/BRAFChairs: Kristen Marrone, Scott Lippman

16:30 16:40 Science Gregory Riely

16:40 16:45 AMG 510 Ramaswamy Govindan

16:45 16:50 MRTX849 (KRAS 9G12C) Pasi Janne

16:50 17:00 Binimetinib (MEK1/2), MEK162 (Binimetinib + Erlotinib) Natasha Leighl

17:00 17:05 ROS126766 (BRAF, MEK1/2) Jose Pacheco

17:05 17:10 LXH254+/-LTT (Pan-RAF) Ibiayi Dagogo-Jack

17:10 17:15 TAK 580 (Non-V600E) (Pan-RAF) Glenwood Goss

17:15 17:20 Regorafenib + MTX (Multi-TKI) Sukhmani Padda

17:20 17:25 SHP2 Inhibitor RMC-4630 Caroline McCoach

17:25 17:30 LY3214966 Alex Adjei

17:30 17:35 Palbociclib + PDO325901 (CDK 4,6 + MEK) Karen Kelly

17:35 17:40 BVD-523 (ERK1/2) Bob Li

17:40 17:45 ASN 007 Michael Cheng


17:55 18:55 POSTER RECEPTION - WEDGEWOOD BALLROOM

18:55 20:05Fellows & Early Career Investigator SessionChairs: Everett Vokes, Leora Horn, Natalie Vokes, Erica Nakajima

Presidential Remarks Tetsuya Mitsudomi

Early Faculty Christine Bestvina

Academic Faculty Natasha Leighl

Academic Physician Scientist Chad Pecot

Community/Hybrid David Spigel

Industry Cathy Pietanza

Government Shakun Malik

Leadership Tetsuya Mitsudomi

Alternative Academics Beyond Clinical Trials Howard West

Patient Advocacy Janet Freeman-Daily

23

FRIDAY, FEBRUARY 21, 2020



7:30 8:30 Session 6 - Surgically Resectable NSCLCChair: Nasser Altorki, David Harpole

7:30 7:35 Neoadjuvant IO (Nivo, Atezo, Sintilimab) David Carbone

7:35 7:40 Neoadjuvant nivo + ipi Tina Cascone

7:40 7:45 Neoadjuvant IO + Chemotherapy Catherine Shu

7:45 7:50 Adjuvant IO + Chemotherapy Nasser Hanna

7:50 7:55 Adjuvant Checkpoint Inhibitors Heather Wakelee

7:55 8:00 Canakinumab Jay Lee

8:00 8:05 Crizotinib David Gerber

8:05 8:10 Osimertinib Colin Blakely

8:10 8:15 LCMC4 Jamie Chaft

8:15 8:20 IO + PCV in ctDNA Positive Adjuvant Post Resection Ross Camidge


8:30 8:50 Debate 3 - Should IO Be Given Before or After Surgery for Resectable NSCLC? Moderators: Shuangge Ma, Peter Koo

8:30 8:40 Before Valerie Rusch

8:40 8:50 After Jessica Donington

8:50 9:55 Session 7 - Stage 3 NSCLC/Combined Modality TherapyChairs: Henry S. Park, Christian Rolfo

8:50 8:55 PACIFIC Trials Everett Vokes

8:55 9:00 Chemo-RT plus Pembrolizumab Greg Durm

9:00 9:05 ECOG-ACRIN 5181 (Chemo-RT plus Durva) Nathan Pennell

9:05 9:10 RT + Atezolizumab Christine Bestvina

9:10 9:15 RT plus Durva for high PD-L1 Exp NSCLC NRG LU004 Steven Lin

9:15 9:20 Chemo RT plus PARP inhibition Primo Lara

9:20 9:25 Chemo RT + Metformin Theodoros Tsakiridis

9:25 9:30 Chemo RT followed by Targeted Therapy: LAURA Study Suresh Ramalingam

9:30 9:35 RTOG 1308: Proton Vs. Photon Jeffrey Bradley




9:35 9:40 RT for oligometastatic NSCLC (NRG LU002) Kristin Higgins

9:40 9:45 SBRT + Immunotherapy Roy Decker



10:15 10:35 Debate 4 - Should RT be given for a patient responding to IO for oligometastatic NSCLC?Moderators: Navid Hafez, David Berz

10:15 10:25 Yes Puneeth Iyengar

10:25 10:35 No Walter Curran Jr.

10:35 11:45 Session 8 - Antibody Drug ConjugatesChairs: Anne Chiang, Vincent Lam

10:35 10:45 Science Pasi Janne

10:45 10:50 DS-1062 (Trop-2) Jacob Sands

10:50 10:55 DS1205 (AXL) Helena Yu

10:55 11:00 IMMUNO132 (Trop-2) Ross Camidge

11:00 11:05 Enapotamab Vedotin Hossein Borghaei

11:05 11:10 ABBV399 (MET) Jyoti Patel

11:10 11:15 DS8201 (HER2) Jose Pacheco

11:15 11:20 ADCT502 (HER2) Grace Dy

11:20 11:25 BGB324 (AXL TKI) David Gerber

11:25 11:30 U3-1402 (HER3-directed ADC Conor Steuer

11:30 11:35 XMT1536 (NaPi2b) Melissa Johnson


11:45 12:40 Session 9 - FGFR/PDFGR/Angiogenesis/VEGFChairs: Emily Lin, Mary Jo Fidler

11:45 11:55 Science John Heymach

11:55 12:00 Nivolumab + vorolanib Heather Wakelee

12:00 12:05 Nivolumab + sitravantinib Kai He

12:05 12:10 EGFR + Bevacizumab or Ramicurumab Balazs Halmos

12:10 12:15 Ramacirumab + IO Rathi Pillai

25



12:15 12:20 Cabozantinib Heather Wakelee

12:20 12:25 Nintedanib + IO Erin Schenk

12:25 12:30 Nintedanib for mutations and its receptors Ticiana Leal


12:40 13:40 LUNCH

13:40 14:40 Best Abstracts - Oral PresentationsChairs: Erin Gillaspie, Brendon Stiles

13:40 13:48OA1: Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Check-point Inhibition in Non-Small Cell Lung Cancer

Biagio Ricciuti

13:48 13:56 OA2: Interferon Gamma Resistance in Setting of LKB1 Loss: Phenotypic Characterization and Investigation of Mechanism Jacob Kaufman

13:56 14:04 OA3: Detection of NRG1 Gene Fusions in NSCLC Sushma Jonna

14:04 14:12OA4: Targeting Inflammatory Monocytes with Dual CCR2/5 Inhibition in Combination with Immune Check-point Inhibition in Lung Squamous Carcinoma

Yvonne Chao

14:12 14:20OA5: MSK-ACCESS for Non-Invasive Somatic Mutation Profiling of Lung Cancers Utilizing Circulating Tumor DNA: A Prospective Clinical Study

Emily Lebow

14:20 14:40 DISCUSSION & Q&A

14:40 16:05 Session 10 - ROS1, TRK, ALK, NRG FusionsChairs: Edward Kaftan, Mary Redman

14:40 14:50 Science Alexander Drilon

14:50 14:55 Entrectinib Robert Doebele

14:55 15:00 Repotrectinib Sai-Hong Ou

15:00 15:05 Crizotinib Jessica Lin

15:05 15:10 Lorlatinib Christine Lovly

15:10 15:15 DS6051b Elaine Shum

15:15 15:20 Ceritinib +/- Trametinib Caroline McCoach

15:20 15:25 Larotrectinib Anna Farago

15:25 15:30 Selitrectinib Alexander Drilon

15:30 15:35 Ensartinib Leora Horn

15:35 15:40 Brigatinib Thomas Stinchcombe




15:40 15:45 Alectinib + bev or other Justin Gainor

15:45 15:50 IO post TKI Corey Langer

15:50 15:55 NRG1 Fusion Inhibitors Stephen Liu



16:25 17:50 Session 11 - RET/MET InhibitorsChairs: Travis Osterman, Rajwanth Veluswamy

16:25 16:35 Science Robert Doebele

16:35 16:40 BLU667 Pralsetinib (RET) Justin Gainor

16:40 16:45 Loxo292 selpercatinib (RET) Alexander Drilon

16:45 16:50 TPX-0046 (RET) Misako Nagasaka

16:50 16:55 RXDX105 Antoinette Wozniak

16:55 17:00 Crizotinib (MET) Mark Kris

17:00 17:05 Savolitinib (MET) Mark Awad

17:05 17:10 Topotinib (MET) Xiuning Le

17:10 17:15 Capmatinib (MET) Rebecca Heist

17:15 17:20 TPX0022 (MET/CSFR1/SRC) Sandip Patel

17:20 17:25 APL-101 Aaron Mansfield

17:25 17:30 Merestinib Julia Rotow

17:30 17:35 REGN 5093 Thomas Marron

17:35 17:40 Sym015 (MET) Ross Camidge


17:50 18:35 Session 12 - MesotheliomaChairs: Giorgio Scagliotti, Antoinette Wozniak

17:50 18:00 Science Harvey Pass

18:00 18:05 Brentuximab Anne Tsao

18:05 18:10 Anetumab Ravtansine + Pembrolizumab Kaushal Parikh

18:10 18:15 WT1 Peptide Vaccine and CAR Matthew Gubens

18:15 18:20 Chemo + IO Patrick Forde

27



18:20 18:25 Neoadjuvant chemo-IO Anne Tsao


19:15 21:15 FACULTY DINNER (BY INVITATION ONLY)

SATURDAY, FEBRUARY 22, 2020



7:00 9:15 Session 13 - Immunotherapy CombinationsChairs: Peter Ujhazy, John Wrangle

7:00 7:10 Science Edward Garon

7:10 7:15 CTLA4 combinations Jarushka Naidoo

7:15 7:20 PD1 and ICOS Charu Aggarwal

7:20 7:25 IO + LAG3 Ashwin Somasundaram

7:25 7:30 IO + CD137 Adrian Sacher

7:30 7:35 IO + CDX1140 (anti-CD40) Rachel Sanborn

7:35 7:40 IO + OX40 Narjust Duma

7:40 7:45 LYC44716 Scott Gettinger

7:45 7:50 Pembrolizumab + vorinostat Ben Creelan

7:50 7:55 IO+ Epacadostat Liza Villaruz

7:55 8:00 Pembrolizumab and itacitinib (JAK1) Joshua Bauml

8:00 8:05 Atezolizumab + Cobimetinib Ryan Gentzler

8:05 8:10 MGA271 Konstantinos Leventakos

8:10 8:15 Phase I Study of TJ004309 (anti-CD73) in Combination with Atezolizumab in Advanced Cancers Francisco Robert

8:15 8:20 Talazoparib Melissa Johnson

8:20 8:25 IO + CCR2/5 Inhibitors Chad Pecot

8:25 8:30 Siglec 15 Roy Herbst

8:30 8:35 CB 839 Aaron Lisberg

8:35 8:40 Pinabulin Lyudmila Bazhenova




8:40 8:45 Monalizumab Joshua Reuss

8:45 8:50 Comparing effect of IO combinations Jack Lee

8:50 8:55 Afatinib + Pembro Benjamin Levy

8:55 9:00 IO + GSK3377794 Ronan Kelly

9:00 9:05 PY314 – anti-TREM2 antibody Erin Schenk



9:30 11:25 Session 14 - mTOR/PI3K/CDK/DNA repair/CHK1/Wee1/PARP inhibitionChairs: Robert Keith, Jeffrey Clarke

9:30 9:35 Rucaparib Shirish Gadgeel

9:35 9:40 Prexasertib Stephen Liu

9:40 9:45 TAK228 (Sapanisertib) Jonathan Riess

9:45 9:50 Taselisib Corey Langer

9:50 9:55 Gedatolisib Zofia Piotrowska

9:55 10:00 ABTL 0812 George Blumenschein

10:00 10:05 mTOR inhibition +PD-1 inhibition Fadlo Khuri

10:05 10:10 P13K Inhibition + PD-1 Inhibition Jennifer Carlisle

10:10 10:15 Sapanisertib + CB-839 Jonathan Riess

10:15 10:20 Sirolimus + Auranofin Helen Ross

10:20 10:25 Trilaciclib Jeffrey Crawford

10:25 10:30 MK 8628 & GSK 525762 Taofeek Owonikoko

10:30 10:35 Olaparib Ben Creelan

10:35 10:40 Talazoparib Taofeek Owonikoko

10:40 10:45 Niraparib Zofia Piotrowska

10:45 10:50 VX-970 Deborah Doroshow

10:50 10:55 AZD 6738 Daniel Morgensztern

10:55 11:00 BAY 1895344 Timothy Yap

11:00 11:05 Adavosertib (AZD1775) Dwight Owen

29



11:05 11:10 AZD 0156 Patricia LoRusso

11:10 11:15 DNA PK inhibition George Simon


11:25 12:10 Session 15 – MiscellaneousChairs: Steven Dubinett, Parneet Cheema

11:25 11:30 Selinexor David Gerber

11:30 11:35 Pevonedistat Angel Qin

11:35 11:40 Nanocisplatin NC 6004 Lyudmila Bazhenova

11:40 11:45 LDOS 47 Afshin Dowlati

11:45 11:50 PF06939999 Rachel Sanborn

11:50 11:55 Auranofin JAK1/STAT3 Helen Ross

11:55 12:00 AG-270 (Agios MAT2A inhibitor) Frederick Wilson


12:10 12:15 WRAP-UP/CONCLUSION

Located in the

STARLIGHTFOYER

EXHIBITORS:FEBRUARY 19-22, 2020 | SANTA MONICA, CALIFORNIA


AmgenAstraZeneca BayerBoehringer IngelheimBristol-Myers SquibbGenentechIASLC MerckNovocureOncology Learning NetworkPfizerTakeda

I N S P I R I N G H O P E T H R O U G H R E S E A R C H

Help us create hope and fund research! Help us create hope and fund research!

D O N AT E T O DAYWHY SUPPORT THE ILC FOUNDATION?The answer is simple. We fund fellowships to support innovative research for conquering lung cancer. Every dollar you give to the ILC Foundation goes straight to research.

IASLC.org/ILC-Foundation

Anytime, Anywhere

Access the TTLC 2020 Conference

Sessions

Never miss out on another presentation!

LIBRARY.IASLC.ORG

Your personal Virtual Meeting Access Code is the same as your Delegate ID Number and can be found on your badge or through your TTLC 2020 registration confirmation email. After you enter your Access Code and confirm your account details, you’ll be able to view any presentations that have been marked as “Now Available.” To start viewing, please visit library.IASLC.org.

Get the 2020 Targeted Therapies

of Lung Cancer Virtual Meeting via

Orchestrating a new investigational approach to researching MET-altered cancers

NCT03175224Phase 1/2 Study of APL-101 in Subjects with c-Met Dysregulation (Overexpression, Amplification or/and EXON 14 Skip Mutations) in Solid Tumors

Featuring APL-101*An investigational, Type 1, selective, and specific c-Met inhibitor currently in clinical development, with preclinical potency against HGF dependent and independent models, favorable preclinical efficacy compared to other selective c-Met inhibitors, and demonstrated blood brain barrier penetration

For full eligibility requirements, please visit ClinicalTrials.gov Interested in enrolling a subject or conducting this trial at your Institution?

Call 1-844-7-SPARTA/1-844-777-2782 (US only) to speak with a representative.

*APL-101 is an investigational agent. Its safety and efficacy have not been established by any agency.

V1 | 21JAN2020 | APL-101-01

Currently Enrolling

1COMMERCIAL PROSPECTUS

H O T T O P I C M E E T I N G :

LIQUID BIOPSYBALTIMORE, MARYLAND | MAY 7-9, 2020

www.IASLC.org/liquidbiopsy

SAVE THE DATE!

#LIQUIDBIOPSY20

Registration Opens

MARCH 1, 2020

Learn about the new advances in liquid biopsy technology and clinical applications, while experiencing professional camaraderie with lung cancer experts.

MEETING CHAIRS:Dr. Maria Arcila, MDDr. David Gandara, MDDr. Christian Rolfo, MD, PhD, MBA

JTO Impact Factor

increases to

12.460!

Ranked 10th among 229 oncology journals

Ranked 3rd among 63 respiratory medicine

journals

JTO is the #1 journal in thoracic malignancies,

according to Editor-in-Chief, Alex A. Adjei, MD, PhD

C O N Q U E R I N G T H O R A C I C C A N C E R S W O R L D W I D E

#NACLC20

SAVE THE DATE!

REGISTRATIONOPENS

APRIL 2020


#NACLC20

SAVE THE DATE!

REGISTRATIONOPENS

APRIL 2020


wclc2020.IASLC.org

REGISTER NOW FOR

WCLC 2020

EXPERIENCEthe latest advances in thoracic oncology at the world’s largest collaborative gathering of lung and thoracic cancer specialists from all disciplines.

Announcing the launch of

A new open access journal from the IASLC

JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the Journal of Thoracic Oncology by offering authors a gold open access publication option and publishing the following article types in particular:

• Phase I trials• Well performed single-arm Phase II trials• Small to moderate-sized randomized Phase II trials• Subset analyses of published trials• Impactful retrospective studies• Database and registry analysis

• Large institutional series• High-quality case reports• Region-specific clinical trials• Subspecialty specific thoracic oncology studies• Selected high-quality meeting reports

Learn more at JTOCRR.org

Help change the landscape of lung cancer treatment for future patients!• New clinical and molecular elements

have been added

• International participation is crucial to the project’s success

• The 9th Edition recommendations will be developed in 2022

NOW CALLING FOR INTERNATIONAL PARTICIPATION

Contribute Data to the IASLC 9th Edition Lung Cancer Staging Project

Financial support may be available

For more information:www.iaslc.org/staging

TIMELINE: The study consists

of lung cancer patients diagnosed between January 1, 2011 and December 31, 2019.

Cases may be submitted through 2021.

IASLC 2020Meetings ScheduleFDA-AACR-IASLC Workshop to Address

the Criticality of Tobacco Use Assessment in Oncology Therapeutic TrialsFebruary 28, 2020 | Silver Springs, MD

#FDAWorkshop20

European Lung Cancer Congress 2020

April 15-18, 2020 | Geneva, Switzerland #ELCC20

Lung Cancer Hot Topic: Liquid Biopsy

May 7-9, 2020 | Baltimore, MD #LiquidBiopsy20

IASLC 2020 World Conference on Lung Cancer

August 9-12, 2020 | Singapore #WCLC20

IASLC 2020 North America Conference on Lung CancerOctober 15-17, 2020 | Chicago, IL

#NACLC20

Lung Cancer Hot Topic: Immunotherapy

November 2020

CONNECT WITH US

linkedin.com

@IASLC

iaslc.lung

facebook.com/IASLC

IASLC

Become an IASLC Member Here are just some of the benefits IASLC members enjoy: › Scientific publications offering: member

access to IASLC Lung Cancer News/Journal of Thoracic Oncology, and discount publication fees for the new open-access Journal of Thoracic Oncology Clinical and Research Reports

› Networking opportunities within the ONLY global, multidisciplinary network dedicated to the study and eradication of thoracic malignancies

› Discounts to the IASLC World Conference on Lung Cancer and other IASLC-sponsored scientific and educational meetings

› Committee opportunities › Access to the IASLC member directory

To learn more about the different levels of membership and benefits, visit: www.iaslc.org/join, visit the IASLC Booth or reach out to [email protected]

Join more than 8,000 thoracic oncology specialists...

JOIN THE IASLC

TODAY!



THANK YOU TO OUR SPONSORS!

D I A M O N D

P L A T I N U M

G O L D

S I LV E R

B R O N Z E

OPENING RECEPTION

#TTLC20



13 100 East Co l fax Avenue | Un i t 10 | Aurora , CO 8001 1 USA | www. IASLC .org

Documents

PROGRAM - IASLC · 2020. 8. 23. · Tejas Patil P05 Real World Data on Safety and Efficacy of 160 mg Daily Dose of Osimertinib in Patients with Sensitizing EGFR Mutant NSCLC with